<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01309022</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN040CT</org_study_id>
    <secondary_id>EXIIST</secondary_id>
    <nct_id>NCT01309022</nct_id>
  </id_info>
  <brief_title>Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)</brief_title>
  <official_title>Immunosuppressive Medications for Previous Participants in Clinical Trial NIS01 (ITN005CT, NCT00014911)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to provide continued acess to immunosuppressive medications
      to subjects from the completed/closed trial ITN005CT (NIS01,NCT00014911). THIS PROTOCOL DOES
      NOT PROVIDE MEDICINES TO DIABETES PATIENTS WHO DID NOT PARTICIPATE IN ITN005CT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study acronym: EXIIST - Extended Immunosuppression in Islet Transplantation

      Islet transplantation is an experimental therapy in people with difficult to control Type 1
      diabetes (T1D). Insulin producing cells (islets) are isolated from a pancreas. After the
      cells are prepared, the islets are put into the subject's liver. These transplanted islets
      may produce insulin that the subject's islets can no longer make. In order to help keep up
      the function of the transplanted islets, immunosuppressive medications must be given
      indefinitely or for as long as the study doctor determines is necessary. The medications
      serve to modify the immune system that normally tries to destroy (reject) new islets.

      Participants in this study have received up to three islet cell infusions as a previous
      participant in the ITN005CT (NIS01) protocol. They also received a maintenance
      immunosuppressive treatment regimen consisting of a combination of orally administered drugs
      (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or
      mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these
      immunosuppressive medications to subjects whose islets continue to function and make
      C-peptide.

      Routine study follow-up visits will occur on an annual and -as warranted basis.
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.</description>
    <other_name>Rapamune®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.</description>
    <other_name>Prograf®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.</description>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolic acid</intervention_name>
    <description>Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.</description>
    <other_name>Myfortic®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in clinical trial ITN005CT (reference: ClinicalTrials.gov record
             NCT00014911) at Harvard University (Massachusetts General Hospital), Washington
             University, or University of Miami.

          -  Immunosuppressive regimen consisting of a single agent or some combination from among
             the following: tacrolimus, sirolimus, mycophenolate mofetil, and mycophenolic acid.

          -  Willingness of participants to use an approved method of contraception before, during,
             and 12 weeks after study participation.

          -  Peak C-peptide &gt;0.1 pmol/mL during a mixed meal tolerance test (MMTT) within 12 months
             of the screening visit.

        Exclusion Criteria:

          -  Inability to understand and sign the informed consent document for this study.

          -  Any medical condition which in the opinion of the investigator should preclude
             participation.

          -  Serum creatinine &gt; 1.6 mg/dL

          -  Insulin requirement &gt; 1.0 IU/kg/day

          -  Hemoglobin A1C (HbA1C) result &gt; 12%

          -  Hypoglycemia unawareness defined as the absence of adequate autonomic symptoms at
             plasma glucose levels of &lt; 54 mg/dL requiring treatment with glucagon, outside
             assistance, or treatment in an emergency room or hospital within a 12-month period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Daniel C. Brennan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.immunetolerance.org</url>
    <description>Immune Tolerance Network (ITN) Web Site</description>
  </link>
  <reference>
    <citation>Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, Secchi A, Brendel MD, Berney T, Brennan DC, Cagliero E, Alejandro R, Ryan EA, DiMercurio B, Morel P, Polonsky KS, Reems JA, Bretzel RG, Bertuzzi F, Froud T, Kandaswamy R, Sutherland DE, Eisenbarth G, Segal M, Preiksaitis J, Korbutt GS, Barton FB, Viviano L, Seyfert-Margolis V, Bluestone J, Lakey JR. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006 Sep 28;355(13):1318-30.</citation>
    <PMID>17005949</PMID>
  </reference>
  <results_reference>
    <citation>Brennan DC, Kopetskie HA, Sayre PH, Alejandro R, Cagliero E, Shapiro AM, Goldstein JS, DesMarais MR, Booher S, Bianchine PJ. Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. Am J Transplant. 2016 Feb;16(2):509-17. doi: 10.1111/ajt.13458. Epub 2015 Oct 3.</citation>
    <PMID>26433206</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>February 5, 2016</last_update_submitted>
  <last_update_submitted_qc>February 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>T1D</keyword>
  <keyword>T1DM</keyword>
  <keyword>Islets of Langerhans Transplantation</keyword>
  <keyword>Pancreatic Islets Transplantation</keyword>
  <keyword>Islet Transplant</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>Mycophenolate mofetil</keyword>
  <keyword>Mycophenolic acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

